Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Rank in Stocks
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Share Price
$4.48
Market Cap
$4.99B
Change (1 day)
-5.20%
Change (1 year)
-41.89%
Country
CN
Trade Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Category
Healthcare
P/S ratio for Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
P/S ratio as of October 2026 TTM: 7.09
According to Shenzhen Salubris Pharmaceuticals Co., Ltd. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 7.09. At the end of 2024 the company had a P/S ratio of 8.59.
P/S ratio history for Shenzhen Salubris Pharmaceuticals Co., Ltd. from 2006 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 7.09 | -44.73% |
| 2025 | 12.83 | 49.35% |
| 2024 | 8.59 | -20.58% |
| 2023 | 10.81 | 4.34% |
| 2022 | 10.36 | 8.68% |
| 2021 | 9.54 | -10.38% |
| 2020 | 10.64 | 128.80% |
| 2019 | 4.65 | 6.64% |
| 2018 | 4.36 | -57.85% |
| 2017 | 10.35 | 29.67% |
| 2016 | 7.98 | -11.93% |
| 2015 | 9.06 | 13.07% |
| 2014 | 8.01 | -17.09% |
| 2013 | 9.66 | 5.70% |
| 2012 | 9.14 | 53.31% |
| 2011 | 5.96 | -52.70% |
| 2010 | 12.61 | 30.91% |
| 2009 | 9.63 | -9.70% |
| 2008 | 10.67 | -33.95% |
| 2007 | 16.15 | -30.69% |
| 2006 | 23.30 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 13.24 | 86.77% |
US
|
|
| 2.74 | -61.33% |
FR
|
|
| 8.98 | 26.59% |
JP
|
|
| 2.54 | -64.18% |
US
|
|
| 3.02 | -57.47% |
CH
|
